By BowTiedBiotech on Substack · 3K+ subscribers · 11 free and 1 paid among the latest 12.
Daily Biotech Public & Private Market Updates, Company Building, Financing, Exit Strategies, and Emerging Science Trends
Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive…
Hello Avatar! Another week of biotech news is in the history books. We are proud to bring you the latest edition of our weekly biotech news fix. The content is designed to be consumed as a quick scroll to bring readers up to…
Hello Avatar! Welcome to another week of biotech analysis. Today’s commentary, as always on Thursday, focuses on the general market update. This week confirmed the playbook. Biotech can rally and capital can return quickly, but…
Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive…
Savara ($SVRA) is a near-term regulatory catalyst centered on the November 22, 2026 FDA PDUFA for MOLBREEVI (molgramostim inhalation solution) in autoimmune pulmonary alveolar proteinosis (autoimmune PAP), a rare lung disease…
Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. This week we break down the next wave…
Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive…
Hello Avatar! Another week of biotech news is in the history books. We are proud to bring you the latest edition of our weekly biotech news fix. The content is designed to be consumed as a quick scroll to bring readers up to…
Hello Avatar! Welcome to another week of biotech analysis. Today’s commentary, as always on Thursday, focuses on the general market update. This week confirmed the playbook. Biotech can rally and capital can return quickly, but…
Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive…
Corcept Therapeutics ($CORT) is a regulatory-reversal catalyst centered on the December 17, 2026 FDA PDUFA for relacorilant in Cushing’s syndrome. The FDA already reviewed the application once and issued a Complete Response…
Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. This week we’re exploring how Beam…